Bintai Kinden unit appointed as Covid-19 vaccine cold chain box distributor

By ASILA JALIL / Pic by BLOOMBERG

Bintai Kinden Corp Bhd’s unit Bintai Healthcare Sdn Bhd will be the exclusive distributor for Greenie Medi Cold Chain Box designed for the storage and distribution of Covid-19 vaccines in Malaysia. 

The company was also appointed as an authorised distributor for the product in South-East Asia namely Brunei, Myanmar, Cambodia, Timor-Leste, Indonesia, Laos, the Philippines, Singapore, Thailand and Vietnam.

Bintai Healthcare signed a distribution agreement with South Korea’s SLAB Asia Co Ltd today to formalise the deal. 

Bintai Kinden MD Ong Choon Lui said the group supports the government’s vaccine distribution initiatives while complementing the existing cold chain infrastructure in providing comprehensive solutions to meet critical needs amid the pandemic. 

“Greenie Medi Cold Chain Box are the ideal solutions for getting temperature-sensitive drugs, biologics and vaccines safely to the end users across Malaysia and beyond,” he said in a statement yesterday. 

The storage box was designed for the exclusive use in transporting and storing medical products at very low temperatures as it keeps the inbox temperature at -70 degrees Celsius for up to 120 hours. 

SLAB Asia is among the leading cold chain equipment manufacturers in South Korea. It operates South Korea’s only ISTA 7D/7E certificate private test lab, which offers its customers international recognised quality assurance. 

ISTA 7D/7E is a test standard set by the Center for Drug Evaluation and Research parked under the US Food and Drug Administration in certifying compatibility and adequacy for transporting medical-grade products.

The deal is expected to contribute positively to the group’s future earnings. 

Bintai Kinden ventured into the distribution of Covid-19 vaccine in October last year. US-based Generex Biotechnology Corp and its subsidiary NuGenerex Immuno-Oncology Inc had given Bintai Healthcare exclusive rights to distribute, sell and commercialise the vaccine in Malaysia and other countries in the region. 

It was also given the first right of refusal to distribute and market the vaccine within Australia, New Zealand and the global halal market.